Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Fountoulakis KN, Yatham L, Grunze H, Vieta E, Young A, Blier P, Kasper S, Moeller HJ.

Int J Neuropsychopharmacol. 2016 Dec 22. pii: pyw100. doi: 10.1093/ijnp/pyw100. [Epub ahead of print] Review.

2.

QT Interval Prolongation Associated with Intramuscular Ziprasidone in Chinese Patients: A Case Report and a Comprehensive Literature Review with Meta-Analysis.

Li XB, Tang YL, Zheng W, Wang CY, de Leon J.

Case Rep Psychiatry. 2014;2014:489493. doi: 10.1155/2014/489493. Epub 2014 Nov 4.

3.

Risperidone versus risperidone plus sodium valproate for treatment of bipolar disorders: a randomized, double-blind clinical-trial.

Moosavi SM, Ahmadi M, Monajemi MB.

Glob J Health Sci. 2014 Jul 29;6(6):163-7. doi: 10.5539/gjhs.v6n6p163.

4.

Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine.

Bartolommei N, Casamassima F, Pensabene L, Luchini F, Benvenuti A, Di Paolo A, Cosentino L, Mauri M, Lattanzi L.

ISRN Psychiatry. 2014 Apr 7;2014:904829. doi: 10.1155/2014/904829. eCollection 2014.

5.

Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study.

Findling RL, Cavuş I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, DelBello MP.

J Child Adolesc Psychopharmacol. 2013 Oct;23(8):531-44. doi: 10.1089/cap.2012.0068. Epub 2013 Oct 10.

6.

Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder.

Findling RL, Cavuş I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, DelBello MP.

J Child Adolesc Psychopharmacol. 2013 Oct;23(8):545-57. doi: 10.1089/cap.2012.0029. Epub 2013 Oct 10.

7.

Current and emerging therapies for the management of bipolar disorders.

El-Mallakh RS, Elmaadawi AZ, Gao Y, Lohano K, Roberts RJ.

J Cent Nerv Syst Dis. 2011 Aug 7;3:189-97. doi: 10.4137/JCNSD.S4441. Print 2011.

8.

Evidence review and clinical guidance for the use of ziprasidone in Canada.

Gardner DM, Murphy AL, Kutcher S, Beaulieu S, Carandang C, Labelle A, Lalonde P, Malla A, Milliken H, O'Donovan C, Schaffer A, Soni J, Taylor VH, Williams R.

Ann Gen Psychiatry. 2013 Jan 24;12(1):1. doi: 10.1186/1744-859X-12-1.

9.

Posttraumatic stress disorder, depression, and health-related quality of life in patients with bipolar disorder: review and new data from a multi-site community clinic sample.

Bajor LA, Lai Z, Goodrich DE, Miller CJ, Penfold RB, Myra Kim H, Bauer MS, Kilbourne AM.

J Affect Disord. 2013 Feb 20;145(2):232-9. doi: 10.1016/j.jad.2012.08.005. Epub 2012 Sep 27. Review.

10.

Effect of initial ziprasidone dose on treatment outcome of korean patients with acute manic or mixed episodes.

Woo YS, Bahk WM, Jo SH, Yoon BH, Lee JG, Kim W, Jeong JH, Seo JS, Min KJ, Jon DI.

Psychiatry Investig. 2011 Sep;8(3):207-13. doi: 10.4306/pi.2011.8.3.207. Epub 2011 Aug 2.

11.

The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder.

Bowden CL.

Neuropsychiatr Dis Treat. 2011;7:87-92. doi: 10.2147/NDT.S9932. Epub 2011 Mar 7.

12.

Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?

Fountoulakis KN, Gonda X, Vieta E, Rihmer Z.

Ann Gen Psychiatry. 2011 Mar 24;10(1):8. doi: 10.1186/1744-859X-10-8.

13.

Weight gain, obesity, and psychotropic prescribing.

Nihalani N, Schwartz TL, Siddiqui UA, Megna JL.

J Obes. 2011;2011:893629. doi: 10.1155/2011/893629. Epub 2011 Jan 17.

14.

Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials.

Yildiz A, Vieta E, Leucht S, Baldessarini RJ.

Neuropsychopharmacology. 2011 Jan;36(2):375-89. doi: 10.1038/npp.2010.192. Epub 2010 Oct 27. Review.

15.

Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis.

Tamayo JM, Zarate CA Jr, Vieta E, Vázquez G, Tohen M.

Int J Neuropsychopharmacol. 2010 Jul;13(6):813-32. doi: 10.1017/S1461145709991246. Epub 2010 Feb 4. Review.

16.

Treating bipolar disorder in the primary care setting: the role of aripiprazole.

Manning JS, McElroy SL.

Prim Care Companion J Clin Psychiatry. 2009;11(5):245-57. doi: 10.4088/PCC.08r00635.

17.
18.

Bipolar disorder.

Geddes JR, Briess D.

BMJ Clin Evid. 2007 Aug 1;2007. pii: 1014. Review.

19.

The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder.

Mundo E, Cattaneo E, Zanoni S, Altamura AC.

Neuropsychiatr Dis Treat. 2006 Jun;2(2):139-48.

20.

Ziprasidone in the treatment of mania in bipolar disorder.

Nicolson SE, Nemeroff CB.

Neuropsychiatr Dis Treat. 2007 Dec;3(6):823-34.

Supplemental Content

Support Center